Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its new Biopharma Experience Center in Hyderabad, Telangana, strengthening its investment in India’s rapidly growing life sciences ecosystem.

The company noted the facility reflects its long-term commitment to advancing biopharmaceutical innovation both locally and globally.

The center was inaugurated by Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Padraig McDonnell, Agilent’s President and CEO, along with senior leaders from India’s pharmaceutical and biopharma industries. 

“Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care,” said Minister Sridhar Babu.

He highlighted that Telangana hosts eight of the top ten global pharma companies, five of India’s leading healthcare chains, and over 230 USFDA-approved manufacturing facilities, contributing nearly one-third of India’s pharmaceutical production and 40 percent of bulk drug exports.

“The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana’s position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem,” the Minster added.

The new center is designed to support the full drug development journey. It brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently.

It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs.

“India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation,” said Padraig McDonnell, CEO, Agilent Technologies.

“Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies to market faster and more efficiently. It also reinforces our support for the ‘Make-in-India’ initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions,” he added.

The center aims to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies, while also serving as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine.

This facility is part of Agilent’s broader three-to-five-year India growth strategy, which includes expanding its footprint, deepening customer partnerships, and positioning India as a strategic hub in Agilent’s global innovation and profitability roadmap.

Earlier this year, the company launched its India Solution Center in Manesar, further solidifying its commitment to enhancing its presence in a priority market.

 “Agilent is already working closely with many of India’s leading biopharma companies. With this center, we aim to strengthen those relationships and co-create solutions that meet the evolving needs of the Indian and global markets,” added McDonnell.

Photo: (L-R) Padraig McDonnell, President and CEO, Agilent; Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana; Bharat Bharadwaj, Vice President and General Manager - APAC, Agilent; Simon May, President, Life Sciences and Diagnostics Group at Agilent Technologies; Nandakumar Kalathil, Country General Manager, Agilent India, at the inauguration of the Agilent Biopharma Experience Center in Hyderabad.